329 related articles for article (PubMed ID: 22628054)
21. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
22. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory biomarkers in stable atherosclerosis.
Kinlay S; Egido J
Am J Cardiol; 2006 Dec; 98(11A):2P-8P. PubMed ID: 17126676
[TBL] [Abstract][Full Text] [Related]
24. Chemokines as therapeutic targets for atherosclerotic plaque destabilization and rupture.
Daissormont IT; Kraaijeveld AO; Biessen EA
Future Cardiol; 2009 May; 5(3):273-84. PubMed ID: 19450053
[TBL] [Abstract][Full Text] [Related]
25. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines--immunological alterations in acute coronary syndrome and stable coronary artery disease.
Szodoray P; Timar O; Veres K; Der H; Szomjak E; Lakos G; Aleksza M; Nakken B; Szegedi G; Soltesz P
Scand J Immunol; 2006 Sep; 64(3):336-44. PubMed ID: 16918703
[TBL] [Abstract][Full Text] [Related]
26. Cellular and molecular mechanisms of statins: an update on pleiotropic effects.
Satoh M; Takahashi Y; Tabuchi T; Minami Y; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M
Clin Sci (Lond); 2015 Jul; 129(2):93-105. PubMed ID: 25927679
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up.
Rallidis LS; Tellis CC; Lekakis J; Rizos I; Varounis C; Charalampopoulos A; Zolindaki M; Dagres N; Anastasiou-Nana M; Tselepis AD
J Am Coll Cardiol; 2012 Nov; 60(20):2053-60. PubMed ID: 23083783
[TBL] [Abstract][Full Text] [Related]
28. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
29. Value of CRP in coronary risk determination.
Mehta JL; Sukhija R; Romeo F; Sepulveda JL
Indian Heart J; 2007; 59(2):173-7. PubMed ID: 19122252
[TBL] [Abstract][Full Text] [Related]
30. Association of inflammatory markers with angiographic severity and extent of coronary artery disease.
Drakopoulou M; Toutouzas K; Stefanadi E; Tsiamis E; Tousoulis D; Stefanadis C
Atherosclerosis; 2009 Oct; 206(2):335-9. PubMed ID: 19264307
[TBL] [Abstract][Full Text] [Related]
31. Novel markers of inflammation in atherosclerosis.
Virani SS; Polsani VR; Nambi V
Curr Atheroscler Rep; 2008 Apr; 10(2):164-70. PubMed ID: 18417072
[TBL] [Abstract][Full Text] [Related]
32. Anti-inflammatory strategies in coronary atherosclerosis.
Burton PB; Daniel TO
Curr Opin Investig Drugs; 2002 Dec; 3(12):1725-8. PubMed ID: 12528306
[TBL] [Abstract][Full Text] [Related]
33. Serum markers of vascular inflammation in dyslipemia.
Francisco G; Hernández C; Simó R
Clin Chim Acta; 2006 Jul; 369(1):1-16. PubMed ID: 16469304
[TBL] [Abstract][Full Text] [Related]
34. [Atherosclerosis and inflammation: the role of C-reactive protein].
Ablij HC; Meinders AE
Ned Tijdschr Geneeskd; 2003 Jan; 147(1):15-20. PubMed ID: 12564292
[TBL] [Abstract][Full Text] [Related]
35. Helicobacter pylori infection in coronary artery disease.
Kowalski M; Pawlik M; Konturek JW; Konturek SJ
J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():101-11. PubMed ID: 17033109
[TBL] [Abstract][Full Text] [Related]
36. Identifying the vulnerable patient with rupture-prone plaque.
Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):3F-10F. PubMed ID: 18549869
[TBL] [Abstract][Full Text] [Related]
37. Cytokines and coronary artery disease: the state of the art.
El-Menyar AA
Crit Pathw Cardiol; 2008 Jun; 7(2):139-51. PubMed ID: 18520532
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory markers and coronary artery disease.
Fichtlscherer S; Heeschen C; Zeiher AM
Curr Opin Pharmacol; 2004 Apr; 4(2):124-31. PubMed ID: 15063355
[TBL] [Abstract][Full Text] [Related]
39. [Mechanisms of coronary plaque formation and disruption].
Matsuo Y; Akasaka T
Nihon Rinsho; 2006 Apr; 64(4):633-41. PubMed ID: 16613179
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers of outcome from cardiovascular disease.
Khuseyinova N; Koenig W
Curr Opin Crit Care; 2006 Oct; 12(5):412-9. PubMed ID: 16943718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
